Staidson (Beijing) BioPharmaceuticals Co., Ltd. (300204.SZ)
CNY 7.48
(0.67%)
CNY 7.48
(0.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -44.22 Million CNY | 82.93% |
| 2022 | -259.12 Million CNY | -249.86% |
| 2021 | -74.06 Million CNY | 17.13% |
| 2020 | -89.36 Million CNY | 74.39% |
| 2019 | -348.97 Million CNY | 3.52% |
| 2018 | -361.68 Million CNY | 9.04% |
| 2017 | -397.62 Million CNY | -37.26% |
| 2016 | -289.68 Million CNY | 70.3% |
| 2015 | -975.41 Million CNY | -8.43% |
| 2014 | -899.57 Million CNY | -10.21% |
| 2013 | -816.26 Million CNY | -1.45% |
| 2012 | -804.61 Million CNY | 7.39% |
| 2011 | -868.77 Million CNY | -4231.55% |
| 2010 | -20.05 Million CNY | 54.02% |
| 2009 | -43.62 Million CNY | -182.59% |
| 2008 | -15.43 Million CNY | -230.86% |
| 2007 | 11.79 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -42.67 Million CNY | -151.18% |
| 2024 Q2 | -16.98 Million CNY | 50.26% |
| 2024 Q1 | -34.15 Million CNY | 22.77% |
| 2023 Q3 | -142.75 Million CNY | 0.95% |
| 2023 FY | -44.22 Million CNY | 82.93% |
| 2023 Q4 | -44.22 Million CNY | 69.02% |
| 2023 Q2 | -144.13 Million CNY | 30.32% |
| 2023 Q1 | -206.86 Million CNY | 20.17% |
| 2022 Q3 | -172.83 Million CNY | -14.33% |
| 2022 Q1 | -92.91 Million CNY | -25.46% |
| 2022 Q2 | -151.16 Million CNY | -62.69% |
| 2022 FY | -259.12 Million CNY | -249.86% |
| 2022 Q4 | -259.12 Million CNY | -49.92% |
| 2021 Q2 | -107.73 Million CNY | 6.94% |
| 2021 Q4 | -74.06 Million CNY | 31.96% |
| 2021 FY | -74.06 Million CNY | 17.13% |
| 2021 Q3 | -108.84 Million CNY | -1.03% |
| 2021 Q1 | -115.76 Million CNY | -29.54% |
| 2020 FY | -89.36 Million CNY | 74.39% |
| 2020 Q1 | -113.51 Million CNY | 67.47% |
| 2020 Q2 | -17.55 Million CNY | 84.54% |
| 2020 Q3 | -136.55 Million CNY | -677.93% |
| 2020 Q4 | -89.36 Million CNY | 34.56% |
| 2019 FY | -348.97 Million CNY | 3.52% |
| 2019 Q4 | -348.97 Million CNY | -159.81% |
| 2019 Q3 | -134.31 Million CNY | 46.02% |
| 2019 Q1 | -263.1 Million CNY | 27.26% |
| 2019 Q2 | -248.81 Million CNY | 5.43% |
| 2018 Q2 | -225.54 Million CNY | 48.23% |
| 2018 Q1 | -435.68 Million CNY | -9.57% |
| 2018 Q4 | -361.68 Million CNY | 35.97% |
| 2018 Q3 | -564.88 Million CNY | -150.45% |
| 2018 FY | -361.68 Million CNY | 9.04% |
| 2017 Q3 | -704.13 Million CNY | -74.1% |
| 2017 Q2 | -404.45 Million CNY | 13.52% |
| 2017 Q1 | -467.68 Million CNY | -33.74% |
| 2017 FY | -397.62 Million CNY | -37.26% |
| 2017 Q4 | -397.62 Million CNY | 43.53% |
| 2016 Q1 | -1.06 Billion CNY | -3.6% |
| 2016 Q3 | -338.95 Million CNY | 64.03% |
| 2016 Q2 | -942.38 Million CNY | 11.87% |
| 2016 FY | -289.68 Million CNY | 70.3% |
| 2016 Q4 | -349.7 Million CNY | -3.17% |
| 2015 Q3 | -997.63 Million CNY | -9.74% |
| 2015 FY | -975.41 Million CNY | -8.43% |
| 2015 Q1 | -896.47 Million CNY | 0.34% |
| 2015 Q2 | -909.07 Million CNY | -1.41% |
| 2015 Q4 | -1.03 Billion CNY | -3.46% |
| 2014 Q4 | -899.57 Million CNY | -9.96% |
| 2014 Q3 | -818.07 Million CNY | -6.85% |
| 2014 FY | -899.57 Million CNY | -10.21% |
| 2014 Q1 | -799.02 Million CNY | 2.11% |
| 2014 Q2 | -765.59 Million CNY | 4.18% |
| 2013 Q3 | -687.02 Million CNY | 1.36% |
| 2013 FY | -816.26 Million CNY | -1.45% |
| 2013 Q4 | -816.26 Million CNY | -18.81% |
| 2013 Q2 | -696.48 Million CNY | 14.13% |
| 2013 Q1 | -811.11 Million CNY | -0.81% |
| 2012 FY | -804.61 Million CNY | 7.39% |
| 2012 Q1 | -874.44 Million CNY | -0.65% |
| 2012 Q2 | -861.57 Million CNY | 1.47% |
| 2012 Q3 | -841.86 Million CNY | 2.29% |
| 2012 Q4 | -804.61 Million CNY | 4.42% |
| 2011 Q4 | -868.77 Million CNY | -1.56% |
| 2011 FY | -868.77 Million CNY | -4231.55% |
| 2011 Q2 | -858.19 Million CNY | -3845.85% |
| 2011 Q3 | -855.45 Million CNY | 0.32% |
| 2011 Q1 | -21.74 Million CNY | -8.44% |
| 2010 Q4 | -20.05 Million CNY | 20.75% |
| 2010 FY | -20.05 Million CNY | 54.02% |
| 2010 Q3 | -25.3 Million CNY | 0.0% |
| 2009 FY | -43.62 Million CNY | -182.59% |
| 2008 FY | -15.43 Million CNY | -230.86% |
| 2007 FY | 11.79 Million CNY | 0.0% |